|Bid||9.02 x 1300|
|Ask||9.03 x 1000|
|Day's Range||8.86 - 9.33|
|52 Week Range||4.33 - 15.52|
|Beta (5Y Monthly)||2.12|
|PE Ratio (TTM)||104.77|
|Earnings Date||Feb 4, 2020 - Feb 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.50|
Is Lannett Company, Inc. (NYSE:LCI) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their […]
Lannett Company, Inc. (NYSE: LCI) today announced that it expects to commence marketing in the coming months a generic version of Adderall XR®, an extended-release mixed salt of a single entity Amphetamine tablet product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate), with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg tablets. Adderall XR® including generic versions have an estimated IQVIA market value of approximately $1.3 billion for the 12 months ending October 2019, although actual generic market values are expected to be lower.
Benzinga Pro's Stocks To Watch For Wednesday Salesforce.com (CRM) - Released Q3 EPS and sales results, which beat analyst estimates. The company issued Q4 EPS guidance of $0.54-$0.55, which is below the ...
Shares of Lannett Company Inc. rallied 11% in premarket trading after it said a clinical trial for its experimental long-acting insulin biosimilar met the primary endpoints. Lannett and HEC Group are developing a biosimilar version of Sanofi's Lantus, which has long been the French drugmaker's top-selling drug. Mylan and Biocon are also expected to bring a Lantus biosimilar to market in 2020, although the U.S. application process has slowed since the Food and Drug Administration sent two complete response letters with corrective actions. Lannett's stock has jumped 78% year-to-date, compared to the S&P 500 , which is up 24%.
Lannett Company, Inc. (NYSE: LCI) today announced positive results from the first human study evaluating insulin glargine that Lannett is developing with its strategic alliance partners within the HEC Group of companies (HEC). Insulin glargine is a long-acting insulin used to treat adults with Type 2 diabetes, as well as adults and pediatric patients with Type 1 diabetes, for the control of high blood sugar.
Moody's Investors Service ("Moody's") affirmed Lannett Company, Inc.'s ("Lannett") B3 Corporate Family Rating and revised the outlook to stable from negative. At the same time, Moody's upgraded the existing senior secured bank credit facilities to B2 from B3 and the Probability of Default Rating (PDR) to B3-PD from Caa1-PD.
It is a pleasure to report that the Lannett Company, Inc. (NYSE:LCI) is up 32% in the last quarter. But will that heal...
Lannett (LCI) delivered earnings and revenue surprises of 10.00% and 4.88%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
PHILADELPHIA , Nov. 6, 2019 /PRNewswire/ -- Financial and Business Highlights: Net Sales, Profitability Exceeded Expectations Launched First-to-Market Posaconazole Expanded Pipeline with Significant ...
Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PHILADELPHIA , Oct. 30, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 first quarter on Wednesday, November 6, 2019 , after ...
The Zacks Analyst Blog Highlights: NRG Energy, Lannett Company, Genesis Healthcare, US Foods and Grocery Outlet